OncoAlert

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit

🚨 We are #OncoAlert | Oncology360°

[OncoAlert @OncoAlert]

The OncoAlert HORIZONS: Breast Cancer Series

Reaction to the lidERA Trial in #BreastCancer

WATCH THE FULL CONVERSATION👇
https://t.co/GwMIN6xwud

In this episode of the OncoAlert Horizons Series, leading breast cancer experts Dr. Sibylle Loibl 🇩🇪and Dr. Rupert Bartsch 🇩🇪 discuss one of the most important topics in early breast cancer management today: the challenges of adjuvant treatment in patients with HR-positive, HER2-negative disease and the emerging role of next-generation oral selective estrogen receptor degraders (SERDs).

HORIZONS FACULTY
@LoiSher, @JavierCortesMD, @BarbaraPistill2, @BianchiniGP, @ElisaAgostinett , Sybille Loibl, Rupert Barsch, François-Clément Bidard , Cristina Saura

@matteolambe, @aftimosp, @E_de_Azambuja, @DrSGraff, @ErikaHamilton9, @double_whammied, @maryam_lustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @SirohiBhawna, @jamecancerdoc, @JavierCortesMD, @JaniceTNBCmets, @Prof_Nadia_H, @nataliagandur, @FernandoOnco, , @to_be_elizabeth, @Lucarecco, @GaiaGriguolo, @JankovicK, @MarioBalsaMD , @to_be_elizabeth , @Dr_Oncologista

[Gil Morgan, MD @weoncologists]

In this episode of the OncoAlert Horizons Series, leading #BreastCancer experts Dr. Sibylle Loibl 🇩🇪and Dr. Rupert Bartsch 🇩🇪 discuss one of the most important topics in early breast cancer management today.

THE FULL CONVERSATION👇 https://t.co/8PH4rwXkFC

In this Clip, they discuss the lidERA trial

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Integration of an echocardiographic motion-management system into photon-based stereotactic arrhythmia radioablation planning

🔗 https://t.co/DqgnUJXGDE
@OncoAlert #OncoAlertAF @UniHeidelberg

Happy to share our latest research⚡️🫀

☢️ Photon-based #STAR planning with an ultrasound probe is feasible.
🔹D0.035 cm3 to the probe below 1 Gy with apical/ parasternal probe placement.
🔹No significant differences in target dose-volume metrics with spared probe.
🔹All dose guidance parameters within clinically acceptable limits.
🔹Results support further investigation of ultrasound-based motion management.

[Yale Cancer Center @YaleCancer]

Beatrice Katsnelson @YaleMed shares an analysis of 2,186 patients with non-small cell #lungcancer #NSCLC #ASTRO26, noting that KEAP1 and SMARCA4 tumor mutations predicted the development of bone mets. The findings suggest molecular profiling at diagnosis could identify high-risk patients and increase surveillance strategies. @HenryParkMD @ASTRO_org @OncoAlert @SmilowCancer @YaleRadOnc @VictorLeeYSM

[CA: A Cancer Journal for Clinicians @CACancerJournal]

An @AmericanCancer report underscores the need for redoubled efforts to optimize early detection while limiting #ProstateCancer overdiagnosis and to address barriers to equitable outcomes, particularly for Native American men.

https://t.co/wSc82rgOaW

@OncoAlert #PCAM

[Pashtoon Kasi MD, MS @pashtoonkasi]

Full paper of my investigator initiated #NEST trial now available in print @CCR_AACR. Trending number 1 based on all the discussion and enthusiasm around neoadjuvant immunotherapy for patients with MSS colorectal cancer. New paradigm.

https://t.co/BPfr75Lvxm

@AACR @OncoAlert

[OncoAlert @OncoAlert]

🚨 Join us at the 2026 International Symposium of Gastrointestinal Oncology (#ISGIO2026), October 2–3, 2026!

🆓 FREE registration with code: ONCOALERT
👉 Register: https://t.co/AFiPe6Q9yG

This multidisciplinary program covers the latest advances in GI cancer research, biomarkers, and personalized treatment. Through expert discussions and interactive sessions, ISGIO will help clinicians navigate the evolving landscape of GI oncology and optimize patient care.

Brought to you by our collaborators at @GotoPER, featuring:
@GIcancerDoc @EileenMOReilly @BeauToskichMD @NiuSanford @SunnieSKim @mdmanishshah @drjasonstarr @Chelsie_Sievers @KristenCiombor @Betzabe100 @whallradonc @OncoThor @DianeReidyLagun @NbmerchantMD @CentralParkWMD @PedroUson @DrElkhoueiry @LizzySmyth1 @BasselElRayesMD @PaulaSmithMDPhD @WuGiOnc

[SEOM @_SEOM]

Bajo el lema 50 años cambiando el significado del cáncer, #SEOM26 propone mirar al pasado para comprender la extraordinaria transformación experimentada por la Oncología Médica, analizar el presente y poner encima de la mesa como se prevé que va a evolucionar la especialidad.

▶️ Lo explica el Dr. @docjavip, coordinador científico del Congreso 👇🏻

[Tyler Seibert MD PhD @TylerSbrt]

🧐nerve-sparing prostate RT?

@ndesai2005 presents Poten-C trial

Unilateral NVB sparing:
❌ did not improve sexual function (primary endpoint)

🤔 urinary function better w NVB sparing

@ASTRO_org #ASTRO26

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

25 fractions ☢️ or 37 — does shorter postprostatectomy RT come with a meaningful toxicity trade-off?

FIVE-YEAR RESULTS OF A PHASE 3 TRIAL OF HYPOFRACTIONATED 🆚 CONVENTIONAL POSTPROSTATECTOMY RADIOTHERAPY: NRG ONCOLOGY GU003

5️⃣ year results from a randomized trial comparing hypofractionated (HYPORT) versus conventionally fractionated postprostatectomy radiotherapy☢️ (COPORT) show similar patient-reported urinary, bowel, and quality-of-life outcomes, with comparable biochemical control.
➡️HYPORT reduced treatment from 37 to 25 fractions but was associated with more grade 3 genitourinary toxicity, particularly cystitis and hematuria.
➡️Despite this increase, no grade 4–5 radiation-related events occurred, supporting HYPORT as an effective and practical postprostatectomy radiotherapy approach. #ProstateCancer

@jmmrad, @RonaldChenMD, @RTendulkarMD, @ndesai2005, @DrPaulNguyen, @DrHowardSandler @RahulTendulkar @PottersMD @TSchroedee

@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists

[Mirrors of Medicine @mirrorsmed]

🚨 Docetaxel after prostatectomy for persistent PSA? NRG GU002 suggests a benefit, but not where you'd expect: the signal was in Decipher LOW/intermediate risk, not high risk. How would you interpret this? 👇

THE ROLE OF DOCETAXEL IN ADDITION TO SALVAGE RADIATION AND ANDROGEN DEPRIVATION IN MEN WITH HIGH-RISK PROSTATE CANCER POST-PROSTATECTOMY: RESULTS OF NRG GU002

#ASTRO26 NRG GU002 randomized 165 men whose PSA failed to nadir ≤0.2 ng/mL after prostatectomy to salvage RT + 6 months ADT, with or without 6 cycles of docetaxel.
➡️The phase II closed early for slow accrual. 5-year freedom from progression: 62.6% vs 48.9% (HR 0.67, one-sided p=0.092).
➡️Locoregional failure improved (HR 0.33); no OS difference. Surprisingly, benefit was concentrated in Decipher low/intermediate-risk patients. More grade 3–4 neutropenia with docetaxel. #ProstateCancer

@mdhurwitzmd, @sartor_oliver, @rtdess, @jmmrad, @APDicker, @MarkMishraMD, @tbottkothari, @DrPaulNguyen, @DrHowardSandler

[Yale Cancer Center @YaleCancer]

Using the Cancer Genome Atlas, @VictorLeeYSM shares that patients with #prostatecancer with TP53 mutations had higher pathologic lymph node involvement (31.8% vs. 13.3%). Noting that incorporating TP53 mutational status into risk stratification models could improve patient selection for elective nodal irradiation. #ASTRO26 @ASTRO_org @YaleRadOnc @OncoAlert @SmilowCancer

[Yale Cancer Center @YaleCancer]

.@MaryKateLawlor presents new data #ASTRO26 showing in 81 patients with stage III uterine serous carcinoma, external beam radiotherapy (EBRT) significantly improved pelvic control and overall survival versus vaginal brachytherapy alone (4-year OS 87% vs. 55%) without increased toxicity, supporting routine EBRT consideration for these patients. @YaleRadOnc @ASTRO_org @SmilowCancer @OncoAlert

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

Tucatinib + trastuzumab + capecitabine after T-DXd in HER2+ MBC.

In this French real world cohort (n=105), TTC showed:
PFS 4.7 months | TTNT 6.6 months | ORR 29.6%

https://t.co/zY342PqZff

@OncoAlert #BreastCancer #bcsm

[Yale Cancer Center @YaleCancer]

.@VictorLeeYSM @YaleRadOnc presents an analysis of patients with stage I–III #breastcancer through MSK-CHORD #ASTRO26 showing TP53 mutations were associated with development of brain mets. Suggesting TP53 mutational status may enhance risk stratification, potentially guiding earlier CNS screening and more targeted treatment approaches. @ASTRO_org @OncoAlert @SmilowCancer

[Miguel Gonzalez Velez, MD @mgonzalezvelMD]

24.5-month median OS in ICI-refractory NSCLC with an oncolytic virus.

CAN-2409 + valacyclovir by @CharuAggarwalMD @StermanDaniel Paul Tak on @jitcancer.

Take: ORR 10.9%, DCR 71.7%; mOS 24.5 mo per-protocol (14.3 mo safety population, n=73).

Activity post-PD1 disease, but logistically intratumoral therapy does not reach most patients.

Any ideas to make intratumoral therapies more feasible? @OncoAlert

#LCSM #thoraciconcology

[OncoAlert @OncoAlert]

Why do some TNBC tumors respond to immunotherapy🧪 while others rapidly develop resistance?

https://t.co/xBtJ8Tpu1i

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics

A multi-cohort study in advanced triple-negative #BreastCancer identifies a transcriptomic signature that stratifies progression-free survival following chemo-immunotherapy.
➡️ Immune-enriched tumors with organized lymphoid architecture were associated with better outcomes, while fibrotic and angiogenic microenvironments, often with PI3K alterations, were linked to poorer outcomes.
➡️ Early progression involved fibrovascular remodeling, macrophage expansion, and immunosuppressive signaling, highlighting coordinated microenvironmental reprogramming as a potential mechanism of immune checkpoint inhibitor resistance.

@NVanRenne, @ElisaAgostinett, @MozejkoMarcin, @Mattia_Rediti, @aftimosp, @AngelZotano, @brasiuniene, @ewa_szczurek,
@LauBuisseret @c_sotiriou @lab_kok @brasiuniene

@hoperugo, @matteolambe, @ErikaHamilton9, @DrSGraff, @aftimosp, @BianchiniGP, @raalbany, @jamecancerdoc, @Icro_Meattini, @stolaney1, @maryam_lustberg, @LoiSher, @stage4kelly, @JaniceTNBCmets, @TanjaSpanic, @christeeny513, @to_be_elizabeth, @MarioBalsaMD, @UOzkerim, @DrVilmaPBarcia, @nataliagandur

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

Ph1 RO7589831 (WRN inhibitor) in MSI-H/dMMR solid tumors
▪️88 patients; 95.5% previously treated with ICIs
▪️MSI efficacy-evaluable population (n=66): ORR 10.6%, DCR 74.2%, mPFS 6.7 months
▪️MSI-H CRC (n=41): ORR 7.3%, mPFS 7.3 months
👉Activity appears modest, but warrants further study. Bev combinations are under evaluation in MSI-H/dMMR CRC; pembro combinations are also planned.
🔗https://t.co/ujS9RpDlb9
@NatureMedicine @OncoAlert

[Daniel E Spratt @DrSpratticus]

@NRGonc GU002 presented by Mark Hurtwitz and team of the benefit of adding doce to salvage RT+ADT.

Overall minimal signal of benefit with expected increase in high grade tox. However, low/intermediate Decipher appeared to benefit most with significant interation found!

Unfortunately trial was substantially under accrued and closed early as providers/patients did not want to add chemo. Not surprising as ADT/doce doublet not even recommended in mHSPC/mAPMS disease.

#ASTRO26 @ASTRO_org @AarmstrongDuke @ChrisSweens1 @jryckman3 @Soum_Roy_RadOnc @AmarUKishan @angela_jia_ @DrHowardSandler @urotoday @wandering_gu @CaPsurvivorship @DrChoueiri

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

Happening right now!

RIGHT CARE, RIGHT COST: ACCESS AND UTILIZATION IN ONCOLOGY

#ASTRO26
Tuesday, 3:45-4:45pm
Room 109

✅✅✅Cost effective analysis, RVU changes, and payer driven utilization variability.